Factors associated with methamphetamine withdrawal symptoms among people who inject drugs

Zhao, Johnathan; Kral, Alex H.; Simpson, Kelsey; Ceasar, Rachel Carmen; Wenger, Lynn; Kirkpatrick, Matt; Bluthenthal, Ricky N.

doi:10.1016/j.drugalcdep.2021.108702

Cited by 17 publications

(8 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the authors reported a significant positive correlation between the total impulsivity score and number of years of METH use only in male participants ( Cservenka and Ray, 2017 ). In addition, Morales et al (2015) documented greater METH craving behavior in women than in men, identified by a drug use survey where participants are instructed to select multiples of 10 between 0 (“not at all”) and 100 (“strongest ever”) that best corresponded with their craving for METH in the last 24 h. Moreover, Zhao et al (2021a) reported that females exhibited more frequent withdrawal symptoms than males. METH withdrawal symptoms in females were also accompanied by higher percentages of withdrawal-related hypersomnia (Females: 77.2% vs Males: 64.8%), fatigue (Females: 77.5% vs Males: 70.3%), and psychomotor retardation (Females: 64.5% vs Males: 57.0%) ( Rungnirundorn et al, 2017 ).…”

Section: Sexual Dimorphism In the Clinical Manifestations Of Meth Use...mentioning

confidence: 99%

Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts

Daiwile

Jayanthi

Cadet

2022

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Section: Sexual Dimorphism In the Clinical Manifestations Of Meth Use...mentioning

confidence: 99%

Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts

Daiwile

Jayanthi

Cadet

2022

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

“…Clinical findings have associated chronic use of methamphetamine with manifestations of withdrawal symptoms including fatigue, sleep disturbance, dysphoria, agitation or psychomotor retardation, increased appetite, depression, and anxiety ( American Psychiatric Association, 2013 ; Zhao et al, 2021 ). Anxiety and depression appear to be prominent and severe especially during the early withdrawal period ( Zhang et al, 2015 ; Ren et al, 2017 ; Luan et al, 2018 ; Luan et al, 2018 ), where longer duration of methamphetamine use was associated with a higher odds ratio of depression, and co-occurring anxiety and psychotic symptoms ( Ma et al, 2018 ).…”

Section: Methamphetamine Use Disordermentioning

confidence: 99%

Goofballing of Opioid and Methamphetamine: The Science Behind the Deadly Cocktail

et al. 2022

View full text Add to dashboard Cite

Globally, millions of people suffer from various substance use disorders (SUD), including mono-and polydrug use of opioids and methamphetamine. Brain regions such as the cingulate cortex, infralimbic cortex, dorsal striatum, nucleus accumbens, basolateral and central amygdala have been shown to play important roles in addiction-related behavioral changes. Clinical and pre-clinical studies have characterized these brain regions and their corresponding neurochemical changes in numerous phases of drug dependence such as acute drug use, intoxication, craving, withdrawal, and relapse. At present, many studies have reported the individual effects of opioids and methamphetamine. However, little is known about their combined effects. Co-use of these drugs produces effects greater than either drug alone, where one decreases the side effects of the other, and the combination produces a prolonged intoxication period or a more desirable intoxication effect. An increasing number of studies have associated polydrug abuse with poorer treatment outcomes, drug-related deaths, and more severe psychopathologies. To date, the pharmacological treatment efficacy for polydrug abuse is vague, and still at the experimental stage. This present review discusses the human and animal behavioral, neuroanatomical, and neurochemical changes underlying both morphine and methamphetamine dependence separately, as well as its combination. This narrative review also delineates the recent advances in the pharmacotherapy of mono- and poly drug-use of opioids and methamphetamine at clinical and preclinical stages.

show abstract

“…Previous clinical studies have shown that METH users often experience psychiatric symptoms, and there was a dose-dependent increase in the incidence of psychotic symptoms among METH users ( McKetin et al, 2006 , 2013 ). Anxiety is one of the most prominent symptoms in the withdrawal period of METH, especially in the acute withdrawal stage ( Zhao et al, 2021 ), and its incidence is related to the duration of METH exposure ( Zorick et al, 2010 ). Furthermore, a study of a large sample of methamphetamine-dependent subjects found that 30.2% of METH users had anxiety disorders induced by METH ( Salo et al, 2011 ).…”

Section: Introductionmentioning

confidence: 99%

Exercise modulates central and peripheral inflammatory responses and ameliorates methamphetamine-induced anxiety-like symptoms in mice

Li²,

Yang

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Anxiety-like symptoms are common symptoms of methamphetamine (METH) users, especially in the acute withdrawal period, which is an important factor for the high relapse rate during METH acute withdrawal. Exercise has been demonstrated to relieve anxiety-like symptoms during METH withdrawal, but the underlying mechanisms of this anti-anxiety effect are still unclear. Activated microglia and abnormal neuroinflammation play an important role in the pathogenesis of anxiety-like symptoms after METH withdrawal. Moreover, peripheral immune factors were also significantly associated with anxiety symptoms. However, the effects of treadmill exercise on microglial function and neuroinflammation in the striatum and hippocampus during acute METH withdrawal have not been reported. In the current study, we found severe peripheral immune dysfunction in METH users during acute withdrawal, which may in part contribute to anxiety symptoms during METH acute withdrawal. We also showed that 2 weeks of METH exposure induced anxiety-like symptoms in the acute withdrawal period. Additionally, METH exposure resulted in increased microglial activation and proinflammatory cytokines released in the mouse striatum and hippocampus during acute withdrawal. We next evaluated the effects of treadmill exercise in countering anxiety-like symptoms induced by METH acute withdrawal. The results showed that anxiety-like symptoms induced by acute METH withdrawal were attenuated by coadministration of treadmill exercise. In addition, treadmill exercise counteracted METH-induced microglial activation in the mouse striatum and various subregions of the hippocampus. Furthermore, treadmill exercise also reversed the increase in proinflammatory cytokines induced by acute METH withdrawal in the mouse striatum, hippocampus and serum. Our findings suggest that the anti-anxiety effect of treadmill exercise may be mediated by reducing microglial activation and regulating central and peripheral inflammatory responses.

show abstract

Factors associated with methamphetamine withdrawal symptoms among people who inject drugs

Cited by 17 publications

References 54 publications

Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts

Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts

Goofballing of Opioid and Methamphetamine: The Science Behind the Deadly Cocktail

Exercise modulates central and peripheral inflammatory responses and ameliorates methamphetamine-induced anxiety-like symptoms in mice

Contact Info

Product

Resources

About